Imunon Inc (IMNN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Imunon Inc stock (IMNN) is currently trading at $2.78. Imunon Inc PS ratio (Price-to-Sales) is 17.94. Analyst consensus price target for IMNN is $21.50. WallStSmart rates IMNN as Sell.
- IMNN PE ratio analysis and historical PE chart
- IMNN PS ratio (Price-to-Sales) history and trend
- IMNN intrinsic value — DCF, Graham Number, EPV models
- IMNN stock price prediction 2025 2026 2027 2028 2029 2030
- IMNN fair value vs current price
- IMNN insider transactions and insider buying
- Is IMNN undervalued or overvalued?
- Imunon Inc financial analysis — revenue, earnings, cash flow
- IMNN Piotroski F-Score and Altman Z-Score
- IMNN analyst price target and Smart Rating
Imunon Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Imunon Inc (IMNN) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and peg ratio. Significant fundamental concerns warrant caution or avoidance.
Imunon Inc (IMNN) Key Strengths (0)
Supporting Valuation Data
Imunon Inc (IMNN) Areas to Watch (6)
Company is destroying shareholder value
Very expensive relative to growth, significant premium
Very expensive at 17.9x annual revenue
Very low institutional interest at 14.07%
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Supporting Valuation Data
Imunon Inc (IMNN) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 0 register as strengths (avg 0/10) while 6 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, PEG Ratio, Price/Sales. Some valuation metrics including PEG Ratio (5.03), Price/Sales (17.94), Price/Book (2.39) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -233.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -233.50% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and PEG Ratio are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IMNN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IMNN's Price-to-Sales ratio of 17.94x trades 106% above its historical average of 8.69x (84th percentile), historically expensive. The current valuation is 87% below its historical high of 136.97x set in Mar 2026, and 25529% above its historical low of 0.07x in Feb 2006.
WallStSmart Analysis Synopsis
Data-driven financial summary for Imunon Inc (IMNN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Imunon Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 125,000 with 0% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 1519% of revenue (2M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -4M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.16, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Imunon Inc.
Bottom Line
Imunon Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Imunon Inc(IMNN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Imunon Inc. is a clinical-stage biotechnology firm focused on pioneering immune-mediated therapies aimed at combating cancer and infectious diseases. Utilizing its proprietary INFECT platform, the company is dedicated to enhancing immune responses that facilitate the effective eradication of malignancies. With a robust pipeline of therapeutics in various stages of clinical evaluation and strategic collaborations that bolster its research capabilities, Imunon is well-positioned to drive notable advancements in immunotherapy, ultimately transforming patient care and establishing a competitive foothold in the biopharmaceutical sector.